HistoSonics™ Partners with Li Ka Shing Foundation to Launch First Histotripsy Programs in Hong Kong
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
MINNEAPOLIS -- Businesswire -- HistoSonics, (www.histosonics.com), the developer and manufacturer of the Edison™ Histotripsy System, announced today the company’s initial partnership in Asia with Hong Kong University receiving their first histotripsy system after a generous donation from the Li Ka Shing Foundation. The Foundation, led by its founder Mr. Li Ka-shing, is a prolific global philanthropic organization with a focused effort in Hong Kong, and is responsible to date for over hk$30 billion in projects involving education, medical services, charity, and anti-poverty programs. As part of the Foundation’s focus on bringing innovative medical advancements to Hong Kong, the Foundation provided the capital to acquire two initial histotripsy systems to the leading public hospitals in Hong Kong, one each to the University of Hong Kong and the Chinese University of Hong Kong. Chinese University of Hong Kong will receive the second histotripsy system early next year to complete the initial gift from Mr. Li.
Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to destroy tissue at cellular and sub-cellular levels in a non-invasive and non-thermal method. Histotripsy offers a promising alternative for patients with liver tumors to avoid certain side effects like surgical site infections, bleeding, and radiation toxicity common to other treatments such as surgery and radiation therapy. The company believes that the novel mechanism of action of their proprietary technology may provide significant advantages to patients, including the ability of the treatment site to recover and resorb quickly. Mr. Li commented, “Treating tumors using the HistoSonics Histotripsy System by forming microbubbles is fascinating” and he believes medical research and innovation can bring hope and economic prospects to the city.
Experts in liver treatment from the University of Hong Kong and the Chinese University of Hong Kong recently underwent training at HistoSonics headquarters in Minneapolis, MN and expect to begin treating patients as early as this week. “We could not be more excited to partner with these two prestigious university hospitals to be the first in Hong Kong to offer our novel therapy to their patients,” said Mike Blue, HistoSonics CEO and President. “Unfortunately, Asia carries a substantial proportion of the world’s population suffering from diseases that cause liver tumors and based on the experiences from our U.S. launch we are confident that we can begin to make an immediate impact on the quality of life of many of the patients who need it most in this region. We are very grateful for the Foundation's very generous gift and Mr. Li’s personal interest in helping patients in Hong Kong,” added Blue. Both Hong Kong based hospitals will be eligible to enroll patients in HistoSonics’ prospective study and post market clinical program, called BOOMBOX, which aims to collect data across a broad number of clinical use cases, and liver tumor pathologies, observing the use of histotripsy across all stages of liver disease.
The Edison Histotripsy System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal, mechanical process of focused ultrasound.
About HistoSonics
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison Histotripsy System in the US and the HistoSonics Histotripsy System in select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN.
For more information on the Edison Histotripsy System please visit: www.histosonics.com/. For patient related information please visit: www.myhistotripsy.com/.
“The pooled #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors” published in Radiology by Mishal Mendiratta-Lala, et.al. is licensed under CC BY 4.0.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828522182/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:HistoSonics
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 서울 평창동 이엔갤러리, 남재현 작가 ‘Moon Over September’ 개인전 개최 - 뉴스와이어
- SAS코리아, 이중혁 신임 대표이사 선임 - 뉴스와이어
- 항공안전기술원, 드론 실증도시 구축사업으로 지자체별 지역 특성 맞춤형 드론 활용 서비스 지
- 대웅제약, 숙취해소제 ‘에너씨슬 퍼펙트샷 쎈’ 출시 - 뉴스와이어
- LIG넥스원, 이라크와 중거리 지대공 유도무기 ‘천궁II’ 공급계약 체결 - 뉴스와이어
- 한국지역난방공사, 2024년도 신입직원 68명 임용 - 뉴스와이어
- 테바소프트 ‘2024 에듀테크 코리아 페어’ 참가… AI 기반 감정 교육 솔루션 공개 - 뉴스와이어
- 두구다, 중기부 ‘팁스’ 선정… AI 기반 의료 경영 최적화 솔루션 ‘메디버니’ 개발 본격화 -
- GC녹십자, 혈우병 환자 개인맞춤형 소프트웨어 ‘WAPPS-HEMO’ 업그레이드 출시 - 뉴스와이어
- 인천창조경제혁신센터-대한항공, 항공우주산업 분야 오픈이노베이션 사업설명회 개최 - 뉴스와